PROKIDNEY CORP.
No SEC Form 4 filings for $PROK in the last 30 days.
See all $PROK insider activity →ProKidney (NASDAQ:PROK) expects Phase III readout for rilparencel in Q2 2027, with enrollment surpassing 500. The therapy showed a 78% slower annual eGFR decline in Phase II. ProKidney aims to complement existing CKD treatments, with manufacturing efficiency improvements planned. Safety data aligns with prior trials, focusing on kidney biopsy-related events.
ProKidney (NASDAQ:PROK) completed enrollment for a pivotal trial of its kidney disease therapy, with results expected in Q2 2027. R&D spending rose to $36.1M, widening losses to $46.4M. Cash reserves dropped to $181.6M, enough to last until mid-2027. Hedge fund holdings fell to 7 from 21, and short interest is 13.83% of the float.
Pereira Brian JG sold 81,929 shares of PROKIDNEY CORP. (PROK) at an average of $1.41 ($1.37–$1.44, $0.12M total) across 3 trades over 2026-08-18 to 2026-08-20.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PROK (PROKIDNEY CORP.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PROK coverage spans financial news, insider activity and technology.
The enrollment milestone signals progress toward a pivotal readout, potentially reducing development risk and supporting a future valuation uplift.
Enrollment completion reduces clinical uncertainty but highlights cash runway constraints, increasing short‑interest pressure.
Insider sell of full position may signal lack of confidence, potentially pressuring the stock.
The insider sale may signal lack of confidence and could pressure the stock lower.
Enrollment completion and updated liquidity and cost trajectory shift the probability-weighted timeline toward the next pivotal readout.
AlphAI scores every news story that mentions PROK with an AI model for sentiment and relevance, and aggregates insider trades from PROKIDNEY CORP.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ProKidney (NASDAQ:PROK) expects Phase III readout for rilparencel in Q2 2027, with enrollment surpassing 500. The therapy showed a 78% slower annual eGFR decline in Phase II. ProKidney aims to complement existing CKD treatments, with manufacturing efficiency improvements planned. Safety data aligns with prior trials, focusing on kidney biopsy-related events.
2 min readProKidney (NASDAQ:PROK) completed enrollment for a pivotal trial of its kidney disease therapy, with results expected in Q2 2027. R&D spending rose to $36.1M, widening losses to $46.4M. Cash reserves dropped to $181.6M, enough to last until mid-2027. Hedge fund holdings fell to 7 from 21, and short interest is 13.83% of the float.
2 min readPereira Brian JG sold 81,929 shares of PROKIDNEY CORP. (PROK) at an average of $1.41 ($1.37–$1.44, $0.12M total) across 3 trades over 2026-08-18 to 2026-08-20.
1 min readPereira Brian JG sold 675,235 indirectly-held shares of PROKIDNEY CORP. (PROK) at an average of $1.41 ($1.37–$1.44, $0.95M total) across 3 trades over 2026-08-18 to 2026-08-20.
1 min readPROKIDNEY CORP. (PROK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights • Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results
6 min readProKidney Corp. (Nasdaq: PROK) appointed Kenneth Locke as Chief Technical Officer, according to a June 2 press release. Locke has 25+ years’ experience in CMC and supply chain, most recently overseeing CMC, Quality and Regulatory at Carisma Therapeutics. The company said the role supports its Phase 3 REGEN-006 (PROACT 1) program and a potential Q2 2027 topline readout.
3 min readControl Empresarial and the Slim family have amended their Schedule 13D/A filing for ProKidney Corp., disclosing a beneficial ownership of 73,842,723 shares of Class A common stock, representing 36.0% of the outstanding shares. This increase in holdings is primarily due to an exchange on April 28, 2026, where Control Empresarial converted 63,118,645 Paired Interests and Class B common stock into Class A common stock. The updated ownership percentage is calculated based on a total of 205,061,550 Class A shares outstanding.
3 min readWINSTON-SALEM, N.C., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( "ProKidney" or the "Company" ) , a leading late clinical-stage cell therapy company focused on chronic kidney disease ( CKD ) , today reported financial results for the third quarter ended September 30, ...
3 min readIn patients with advanced chronic kidney disease ( CKD ) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progression
3 min readWINSTON-SALEM, N.C., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( "ProKidney" or the "Company" ) , a leading late clinical-stage cell therapy company focused on CKD, today presented full results from the Phase 2 REGEN-007 trial evaluating rilparencel in patients with ...
3 min read
